Comparison of three different types of donor hematopoietic stem cell transplantation for intermediate and high-risk myelodysplastic syndrome
10.3760/cma.j.issn.0253-2727.2017.04.008
- VernacularTitle: 不同异基因造血干细胞移植方式治疗167例中高危骨髓增生异常综合征疗效比较
- Author:
Yue LU
1
;
Tong WU
;
Yanli ZHAO
;
Xingyu CAO
;
Deyan LIU
;
Min XIONG
;
Jiarui ZHOU
;
Jianping ZHANG
;
Zhijie WEI
;
Ruijuan SUN
;
Daopei LU
Author Information
1. Department of Bone Marrow Transplantation, Hebei Yanda Ludaopei Hospital, Langfang 065200, China
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Myelodysplastic syndrome;
Prognosis
- From:
Chinese Journal of Hematology
2017;38(4):301-306
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate three different types of donor hematopoietic stem cell transplantation (HSCT) for intermediate and high-risk myelodysplastic syndrome (MDS) .
Methods:Between August 2001 and May 2015, 167 consecutive patients with MDS in intermediate and high-risk who underwent allogeneic HSCT were analyzed retrospectively.
Results:With the median follow up of 60 (12-177) months, The total 5-year DFS was 67.8% (95%CI 60.0%-75.6%) . Among three different types of donor, 5-year DFS rates were 68.0% (95%CI 54.1%-81.9%) in MSD-HSCT vs 77.4% (95%CI 62.1%-92.7%) in MUD-HSCT vs 64.0% (95% CI 52.4%-75.6%) in Haplo-HSCT (P=0.632) , respectively. Univariate analysis showed that median disease course before HSCT was the influencing factor of DFS (P=0.018) . Five-year relapse and TRM had no correlation with the above-mentioned factor.
Conclusions:Haplo-HSCT for intermediate and high-risk MDS achieved similar effect produced by MUD or MSD, Haplo-HSCT could be used as an important alternative donor. allo-HSCT must be performed on intermediate and high-risk MDS patients as early as possible after diagnosis.
